ESMO Real World Data and Digital Oncology最新文献

{"title":"Real-world outcomes following PARP inhibitor maintenance in ovarian cancer by BRCA status: a retrospective cohort study","authors":"K. Zucker ,&nbsp;B. Pickwell-Smith ,&nbsp;A. Samani ,&nbsp;A. Sujenthiran ,&nbsp;H. Pittell ,&nbsp;P. Mpofu ,&nbsp;G. Hall","doi":"10.1016/j.esmorw.2025.100659","DOIUrl":"10.1016/j.esmorw.2025.100659","url":null,"abstract":"<div><h3>Background</h3><div>The introduction of poly (adenosine-diphosphate ribose) polymerase inhibitors (PARPis) has significantly improved progression-free survival for patients with ovarian cancer after response to first-line platinum-based chemotherapy. Yet, there are concerns that PARPi may compromise response to further platinum due to cross-resistance mechanisms. This study investigates the clinical effectiveness of chemotherapy post-progression on PARPi maintenance therapy after initial platinum-based treatment for ovarian cancer, regardless of <em>BRCA</em> mutations, using real-world data. Additionally, this study summarises results across randomised trials of PARPi as first-line maintenance.</div></div><div><h3>Materials and methods</h3><div>This study used a United States-based electronic health record-derived de-identified database. A retrospective descriptive analysis was conducted on patients with ovarian cancer diagnosed from 1 January 2015 onwards. Patient data were collected, including <em>BRCA</em> and homologous recombination deficiency (HRD) status. Time to next treatment (TTNT), treatment-free interval (TFI), and the impact of <em>BRCA</em> and HRD status were assessed.</div></div><div><h3>Results</h3><div>Among 3649 patients, 81% had known <em>BRCA</em> status, of whom 83% were <em>BRCA</em>-negative, 17% were <em>BRCA</em>-positive, and 19% had unknown <em>BRCA</em> status. The majority (80%) had unknown HRD status. Notably, 17% received first-line PARPi. Patients with <em>BRCA</em> mutations displayed longer TTNT and TFI when receiving first-line PARPi initially. However, after receiving subsequent treatments, <em>BRCA</em>-mutated and non-mutated patients demonstrated shorter TFI and TTNT intervals, suggesting a possible influence of PARPis on subsequent chemotherapy efficacy.</div></div><div><h3>Conclusions</h3><div>The study underscores previous concerns that initiating PARPi in the first line may impact treatment duration and intervals for subsequent therapies in patients with ovarian cancer. Future investigations should explore the interplay of PARPi maintenance in the first-line setting, HRD status, and response to subsequent platinum-based therapies.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"11 ","pages":"Article 100659"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145926646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world demographics, clinical characteristics, and testing and treatment patterns in patients with non-small-cell lung cancer and extensive-stage small-cell lung cancer in Belgium: the AIBED study","authors":"K.M. Muylle ,&nbsp;L. Decoster ,&nbsp;D. Verleyen ,&nbsp;P.R. Germonpre ,&nbsp;I. Masuy ,&nbsp;B. Verheyden ,&nbsp;C.L. Oeste ,&nbsp;E. Callewaert ,&nbsp;S. Derijcke ,&nbsp;E. Wauters ,&nbsp;A. Janssens ,&nbsp;A. Verbiest","doi":"10.1016/j.esmorw.2025.100668","DOIUrl":"10.1016/j.esmorw.2025.100668","url":null,"abstract":"<div><h3>Background</h3><div>Real-world evidence is essential to understand the implementation of lung cancer treatments. This study describes the characteristics, testing patterns, and treatment of lung cancer patients in Belgium.</div></div><div><h3>Methods</h3><div>This multicenter study used routinely collected longitudinal electronic health record data from five Belgian hospitals (2019-2021). Natural language processing was used to process unstructured data, which was combined with structured data to generate an Observational Medical Outcomes Partnership (OMOP) common data model (OMOP-CDM) data warehouse. We generated a lung cancer cohort and subcohorts of special interest: stage IB-IIIB resected non-small-cell lung cancer (NSCLC), unresected stage III NSCLC, (EGFR-mutated) stage IV NSCLC, and extensive-stage small-cell lung cancer (ES-SCLC).</div></div><div><h3>Results</h3><div>We included 1952 patients, of whom 87% (1699) had NSCLC and 13% (253) SCLC (86.6% ES-SCLC). Stage IB-IIIB resected NSCLC included 17.3%, unresected stage III NSCLC 12.3%, and stage IV NSCLC 45.0% of NSCLC patients. Brain metastasis around diagnosis was reported in 16.4% of stage IV NSCLC (22.3% in EGFR mutated) and 15.1% of ES-SCLC patients. Across NSCLC subcohorts, 53.9% of patients had a programmed death-ligand 1 (PD-L1)- positive tumor (≥1%) and 12.7% an EGFR mutation-positive tumor. In stage IB-IIIB resected NSCLC patients, resection status was retrieved for 83.0% of patients, of whom 93.0% had complete resection. Among 327 stage III NSCLC patients, 63.9% (<em>n</em> = 209) were unresected, 36.7% (<em>n</em> = 120) had a PD-L1-positive tumor, 18.3% (<em>n</em> = 60) completed chemoradiotherapy, and 11.3% (<em>n</em> = 37) initiated durvalumab.</div></div><div><h3>Conclusions</h3><div>This is the first Belgian study to provide real-world insights into patient trajectories in lung cancer patients leveraging artificial intelligence technologies.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"11 ","pages":"Article 100668"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction models of adverse outcomes following surgery and radiotherapy for breast cancer: a systematic review","authors":"H. Asfour ,&nbsp;B. Wang ,&nbsp;H. Zhou ,&nbsp;A. Al Janapy ,&nbsp;N.G. Patel ,&nbsp;R.P. Symonds ,&nbsp;C.J. Talbot ,&nbsp;T. Rattay","doi":"10.1016/j.esmorw.2026.100690","DOIUrl":"10.1016/j.esmorw.2026.100690","url":null,"abstract":"<div><div>Breast surgery and radiotherapy are the most common treatment modalities for breast cancer, although both may have side-effects that can affect quality of life. Being able to identify patients at risk of adverse outcomes would enable optimisation of individualised treatment plans to improve the experience of breast cancer survivors. A systematic review of prediction models for adverse outcomes following surgery and radiotherapy for breast cancer was conducted. PubMed, Medline, Scopus, Web of Science, and CINAHL databases were searched using relevant key words and Medical Subject Heading terms. The search yielded 5376 articles, of which 33 articles were included. Data were extracted on study design, sources of training and test/validation data, predictors, outcomes, model performance, and validation. Several prediction models for adverse outcomes following breast surgery with or without radiotherapy have been developed. For short-term side-effects, these include the American College of Surgeons National Surgical Quality Improvement Program Surgical Risk Calculator, the Breast Reconstruction Risk Assessment score, and the Breast Cancer Surgery Risk Calculator. Despite the relatively large training datasets used in the development of prediction models, they suffer from a relative lack of external validation. There is as yet no externally validated prediction model for long-term adverse outcomes, although machine learning and multiscale finite element models show promise. Overall, while significant advancements have been made in developing these prediction models, the majority are not yet ready for widespread clinical implementation. This systematic review also highlights a lack of prediction models for long-term side-effects and more complex outcomes, suggesting areas for future research.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"11 ","pages":"Article 100690"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147421107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro)","authors":"A. Anton ,&nbsp;C. Steer ,&nbsp;M. Arasaratnam ,&nbsp;J. Torres ,&nbsp;A. Weickhardt ,&nbsp;M. Warren ,&nbsp;A.R.A. Mislang ,&nbsp;A.A. Azad ,&nbsp;A. Linton ,&nbsp;A. Smith ,&nbsp;S. Rai ,&nbsp;W. Hong ,&nbsp;P. Gibbs ,&nbsp;B. Tran","doi":"10.1016/j.esmorw.2025.100677","DOIUrl":"10.1016/j.esmorw.2025.100677","url":null,"abstract":"<div><h3>Background</h3><div>Androgen receptor pathway inhibitors (ARPIs) are commonly used in older patients with metastatic castration-resistant prostate cancer (mCRPC). Treatment selection is informed by considering adverse event (AE) profiles, given that there are no previous randomised phase III comparison trials.</div></div><div><h3>Materials and methods</h3><div>This prospective registry-based randomised trial utilised the electronic Prostate Cancer Australian Database to collect clinical data. Patients aged ≥75 years who were suitable to receive abiraterone or enzalutamide for mCRPC were randomised to receive either ARPI treatment, stratified by prior docetaxel use. Telephone assessments were conducted at baseline and 12 weeks, including the Blessed Orientation-Memory-Concentration (BOMC) tool, Geriatric Depression Scale (GDS), and Falls Risk Questionnaire (FRQ). Descriptive statistics and mixed-effects linear regression were used to compare groups, including changes in assessment scores from baseline. Cox proportional hazards modelling was used to analyse effects of variables on time to treatment failure (TTF) and overall survival (OS).</div></div><div><h3>Results</h3><div>We enrolled 76 men between June 2019 and September 2023, but closed due to slow accrual in December 2023. Nineteen (25%) had prior docetaxel. The median age was 81 years (interquartile range 77-85 years). The mean score change at 12 weeks trended higher in those receiving enzalutamide for each of BOMC (+0.64 versus −0.51, <em>P</em> = 0.46), GDS (+0.70 versus +0.06, <em>P</em> = 0.06), and FRQ (+1.4 versus −0.12, <em>P</em> = 0.06). A higher baseline GDS score was associated with shorter TTF [hazard ratio (HR) 1.3, 95% confidence interval (CI) 1.05-1.6, <em>P</em> = 0.014], as was higher baseline FRQ score (HR 1.12, 95% CI 1.09-1.22, <em>P</em> = 0.012). There were no differences in TTF, OS, prostate-specific antigen response, or AE rates between treatment groups.</div></div><div><h3>Conclusions</h3><div>Our results highlight the importance of individualised assessment of cognition, depression, and falls risk in older patients commencing ARPI treatment.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"11 ","pages":"Article 100677"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing artificial intelligence and multidisciplinary tumor board decision making in real-world cancer care: a prospective blinded concordance study☆","authors":"R. Pinninti ,&nbsp;R. Gullapalli ,&nbsp;K.M. Mallavarapu ,&nbsp;R. Singareddy ,&nbsp;S.S. Nekkanti ,&nbsp;P. Nikhil ,&nbsp;S. Shukla ,&nbsp;N. Hariharan ,&nbsp;D. Gudipudi ,&nbsp;K. Suseela ,&nbsp;V. Koppula ,&nbsp;T.S. Rao ,&nbsp;S.J. Rajappa","doi":"10.1016/j.esmorw.2026.100688","DOIUrl":"10.1016/j.esmorw.2026.100688","url":null,"abstract":"<div><h3>Background</h3><div>Multidisciplinary tumor boards (MDTs) integrate expertise, enhance diagnostic accuracy, improve adherence to evidence-based guidelines, and facilitate individualized treatment planning. Recent advances in artificial intelligence (AI) help streamline these processes, though prospective real-world evaluations remain limited.</div></div><div><h3>Materials and methods</h3><div>We conducted a prospective, non-interventional, blinded concordance study at a tertiary cancer center. Consecutive cases discussed at institutional MDTs between January 2025 and June 2025 were screened for eligibility. Cases with comprehensive clinical information and documented MDT decisions were included. Anonymized vignettes were input into ChatGPT® using a standardized template. A blinded expert reviewer assessed concordance using a predefined three-point scale. The primary outcome was mean concordance score (MCS) for primary clinical query. Secondary outcomes were domain-specific concordance and reviewer-perceived clinical acceptability of AI decisions.</div></div><div><h3>Results</h3><div>A total of 106 cases (median age 53 years) were analyzed, spanning 21 tumor sites, with the most common being breast (17%), ovary (10.4%), and esophagus (8.5%). Disease stages at MDT discussion were early (20.8%), locally advanced (49.1%), <em>de novo</em> metastatic (8.5%), and recurrence (21.7%). The most frequent primary query was treatment intent and multidisciplinary care (66.1%). MCS for the primary clinical query was 1.42, corresponding to ∼71% of the maximum possible concordance on a 0-2 scale. The highest concordance was noted for treatment intent (84.6% full concordance), radiotherapy (73.4%), and surgical decisions (71.8%), and the lowest for diagnostic (51.6%) and systemic therapy (56%). AI decisions were perceived clinically acceptable for real-world application in 78.3% of cases, comparable to MDT decisions (75.5%).</div></div><div><h3>Conclusions</h3><div>In a prospective real-world setting, moderate-high concordance was observed for AI and MDT decisions across multiple domains. These findings support further evaluation of AI as a decision-support tool within multidisciplinary oncology care.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"11 ","pages":"Article 100688"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Cost-effectiveness of first-line osimertinib informed by electronic medical records via text-mining: a real-world Italian case study of EGFR-mutated advanced NSCLC patients”","authors":"F. Corso ,&nbsp;P. Baili ,&nbsp;F. Scotti ,&nbsp;L. Mazzeo ,&nbsp;V. Torri ,&nbsp;G. Lo Russo ,&nbsp;C. Proto ,&nbsp;C. Giani ,&nbsp;M. Ganzinelli ,&nbsp;R.M. di Mauro ,&nbsp;A. Cappozzo ,&nbsp;A.M. Paganoni ,&nbsp;A. Prelaj ,&nbsp;F. Ieva","doi":"10.1016/j.esmorw.2026.100686","DOIUrl":"10.1016/j.esmorw.2026.100686","url":null,"abstract":"","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"11 ","pages":"Article 100686"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147538502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘Superhuman performance on urology board questions using an explainable language model enhanced with European Association of Urology guidelines’","authors":"M.J. Hetz ,&nbsp;N. Carl ,&nbsp;S. Haggenmüller ,&nbsp;C. Wies ,&nbsp;J.N. Kather ,&nbsp;M.S. Michel ,&nbsp;F. Wessels ,&nbsp;T.J. Brinker","doi":"10.1016/j.esmorw.2026.100687","DOIUrl":"10.1016/j.esmorw.2026.100687","url":null,"abstract":"","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"11 ","pages":"Article 100687"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147538506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study","authors":"M.E. Cazzaniga ,&nbsp;V. Cogliati ,&nbsp;E. Rossi ,&nbsp;I. Paris ,&nbsp;F. Borella ,&nbsp;G. Moretti ,&nbsp;O. Garrone ,&nbsp;M. Pistelli ,&nbsp;R. Palumbo ,&nbsp;A. Ferro ,&nbsp;P. Vici ,&nbsp;U. De Giorgi ,&nbsp;S. Madaro ,&nbsp;L. Coltelli ,&nbsp;M. Giordano ,&nbsp;A.R. Gambaro ,&nbsp;S.V.L. Nicoletti ,&nbsp;F. Zustovich ,&nbsp;E. Landucci ,&nbsp;T. Gamucci ,&nbsp;S. Capici","doi":"10.1016/j.esmorw.2025.100665","DOIUrl":"10.1016/j.esmorw.2025.100665","url":null,"abstract":"<div><h3>Background</h3><div>Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). However, treatment resistance and progression remain significant challenges, and optimal second-line strategies are not well defined.</div></div><div><h3>Materials and methods</h3><div>HERMIONE-13 is a multicentre, observational study conducted across 18 Italian centres, including both retrospective and prospective cohorts. The study aimed to describe real-world second-line treatment patterns following progression on CDK4/6i and to identify factors influencing therapeutic decisions. Clinical outcomes, including real-world progression-free survival (rwPFS) and overall survival (OS), were also evaluated.</div></div><div><h3>Results</h3><div>Among 254 assessable patients, 67.3% received chemotherapy (CHT) and 32.7% received ET ± targeted therapy (TT) as second-line treatment. The most common regimens included capecitabine and everolimus plus exemestane. Multivariable analysis showed that younger age, prior fulvestrant use, and shorter CDK4/6i duration were associated with CHT choice. Median rwPFS was 5.8 months for CHT and 5.3 months for ET ± TT. Median OS was longer in the ET ± TT group (3.8 versus 2.3 years). Metronomic CHT showed promising activity with a median rwPFS of 9.7 months.</div></div><div><h3>Conclusions</h3><div>In the Italian real-world setting, CHT remains the predominant second-line choice after CDK4/6i failure, though ET ± TT may offer comparable or superior outcomes in selected patients. Treatment decisions are influenced by clinical history and patient characteristics. These findings underscore the need for personalized approaches and molecular profiling to guide post-CDK4/6i therapy in HR-positive/HER2-negative MBC.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"11 ","pages":"Article 100665"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145926701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital symptom monitoring and activity tracking in chemoradiation—lessons from the CAM experience","authors":"J. Fu ,&nbsp;A. Pepin ,&nbsp;C. Hollawell ,&nbsp;K. Tang ,&nbsp;J.S. Bryer ,&nbsp;A. Munter ,&nbsp;S. Sinha ,&nbsp;A. Goel","doi":"10.1016/j.esmorw.2026.100683","DOIUrl":"10.1016/j.esmorw.2026.100683","url":null,"abstract":"<div><div>Artificial intelligence (AI) is increasingly being explored as a way to improve supportive care during chemoradiotherapy (CRT). Through our CAM 1.0 and CAM 2.0 studies, we examined how AI-supported remote patient monitoring could be integrated into CRT care, revealing both its potential benefits and its challenges in real-world implementation. We observed how AI can facilitate remote patient monitoring beyond routine visits, yet also how it may create additional tasks for providers, magnify digital inequities, and leave patients still seeking human connection. These experiences underscore that AI’s impact in oncology will be defined not only by its technical capabilities but by how it fits into workflows, addresses barriers to access, and preserves the relational aspects of care. This perspectives piece aims to highlight the practical insights from CAM 1.0 and 2.0 that may inform how oncologists, developers, and health systems approach future AI integration into oncology workflows, particularly in the context of CRT. NCT: <span><span>NCT05318027</span><svg><path></path></svg></span></div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"11 ","pages":"Article 100683"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid biopsies using circulating tumor DNA for surveillance of gastrointestinal cancers in Hispanics: first real-world data report","authors":"C. Cardona-De Jesús ,&nbsp;H. Centeno-Girona ,&nbsp;F. Garau-Rolón ,&nbsp;H. Melero-Rodríguez ,&nbsp;I. Alicea ,&nbsp;M. Cruz-Correa","doi":"10.1016/j.esmorw.2025.100652","DOIUrl":"10.1016/j.esmorw.2025.100652","url":null,"abstract":"<div><h3>Background</h3><div>Malignant tumors release circulating tumor DNA (ctDNA) into the bloodstream, providing insights into tumor-specific mutations and pathways driving cancer progression. ctDNA testing is currently approved as a type of liquid biopsy to monitor disease burden and detect minimal residual disease (MRD). This study aimed to evaluate the adoption of ctDNA testing in a community oncology practice and assess the overall diagnostic performance of ctDNA and its association with disease progression in stage IV colorectal cancer (CRC), as determined by imaging studies.</div></div><div><h3>Patients and methods</h3><div>This retrospective study analyzed the medical records of 88 patients with gastrointestinal cancers (80 CRC, 5 gastric, 3 esophageal) who underwent ctDNA molecular testing between January 2020 and April 2022. Electronic medical records from patients aged ≥21 years who had two or more ctDNA tests with concurrent imaging studies or a pathology-confirmed CRC, gastric cancer, or esophageal cancer diagnosis were evaluated.</div></div><div><h3>Results</h3><div>At baseline, 47 (53.4%) patients had negative and 41 (46.6%) had positive results. Most patients had CRC (90.1%). In stage IV CRC, ctDNA was increasing before radiologic progression in all documented cases (100%), with a median lead time of 2.5 months (range 0.5-15 months). In early-stage CRC (I-III), ctDNA preceded radiologic progression in 40% of cases, with a median lead time of 6 months (range 6-10 months).</div></div><div><h3>Conclusions</h3><div>Using real-world data, we report the first-time results of the ctDNA testing adoption in a community oncology setting among patients with gastrointestinal cancers, predominantly CRC. Our findings suggest that integration of ctDNA testing may support disease monitoring in routine clinical practice.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"11 ","pages":"Article 100652"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}